These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21817075)

  • 21. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis.
    Brown JN; Kemp DW; Brice KR
    Pharmacotherapy; 2009 Apr; 29(4):468-72. PubMed ID: 19323622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epoetin dosing and dialysis facility ownership.
    Regidor DL; Kalantar-Zadeh K; Kovesdy CP
    JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
    [No Abstract]   [Full Text] [Related]  

  • 23. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB
    Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Darbepoetin alfa and chronic kidney disease.
    Hampl H; Kovesdy CP; Kalantar-Zadeh K
    N Engl J Med; 2010 Feb; 362(7):654; author reply 655. PubMed ID: 20187260
    [No Abstract]   [Full Text] [Related]  

  • 25. Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa.
    Walker R; Pussell BA;
    Nephrology (Carlton); 2007 Oct; 12(5):448-51. PubMed ID: 17803467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should all patients with chronic kidney disease receive an EPO-type drug?
    Berns JS
    Cleve Clin J Med; 2006 Mar; 73(3):298-300. PubMed ID: 16548453
    [No Abstract]   [Full Text] [Related]  

  • 27. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
    Itri LM
    Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
    Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE; ;
    J Clin Oncol; 2008 Jan; 26(1):132-49. PubMed ID: 17954713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anemia management in CKD patients in the era of new US Food and Drug Administration recommendations on the use of erythropoiesis-stimulating agents.
    Kaufman JS
    Am J Kidney Dis; 2013 Feb; 61(2):191-3. PubMed ID: 23318011
    [No Abstract]   [Full Text] [Related]  

  • 30. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adherence to treatment with erythropoiesis stimulating agents].
    Pérez Díez C; Navarro Aznárez H; Lou Arnal LM
    An Sist Sanit Navar; 2020 Apr; 43(1):81-85. PubMed ID: 32242547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O; Bailey RA; Stephenson JJ; Singer J
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Epoetin in cancer patients. Guidelines of the ASCO and the ASH for evidence-based clinical practice].
    Del Mastro L; ;
    Tumori; 2003; 89(4):1-12. PubMed ID: 14606657
    [No Abstract]   [Full Text] [Related]  

  • 37. The use of darbepoetin in infants with chronic renal impairment.
    Durkan AM; Keating LE; Vigneux A; Geary DF
    Pediatr Nephrol; 2006 May; 21(5):694-7. PubMed ID: 16565871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epoetin alfa: to give or not to give.
    Dang C; Hudis C; Norton L
    J Natl Cancer Inst; 2013 Jul; 105(14):1001-3. PubMed ID: 23860203
    [No Abstract]   [Full Text] [Related]  

  • 39. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY; Chu TS; Huang JW; Wu MS; Wu KD
    J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.